Pharma Mar SA
70.60
EUR
+0.10
(+0.14%)
ISIN
ES0169501022
Return %
Stock
S&P 500
1Y
-6.80
14.20
3Y
128.48
81.12
5Y
-1.37
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- José Maria Fernández de Sousa-Faro
- Full Time Employees
- 515
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Avenida de los Reyes, 1 Colmenar Viejo MA Spain 28770
- IPO Date
- Nov 2, 2015
- Website
- pharmamar.com
- Similar Companies
- Business
- PharmaMar S.A. is a Spain-based biopharmaceutical company focused on the discovery, development, and commercialization of novel anticancer medicines derived from marine organisms and related biotechnologies; it specializes in oncology therapeutics, including marine-derived compounds and targeted therapies, with a portfolio spanning clinical and preclinical candidates and companion diagnostics, alongside research and development services for collaborative programs. PharmaMar operates primarily in Europe, the Americas, and other international markets, with commercial activities in Spain and select European Union countries, and maintains research facilities and manufacturing capabilities in Spain. Main products and services: marine-derived anticancer agents including small-molecule and biologic oncology therapeutics; drug discovery and development services; preclinical and clinical trial collaborations; supply and distribution of approved oncology medicines; research collaborations and licensing of pipeline assets; companion diagnostics development; regulatory and pharmacovigilance support; manufacturing and formulation development; API production and specialty pharmaceutical services; commercialization and marketing of oncology products in selected geographies. Latest major company changes: enters strategic partnerships and licensing agreements to advance pipeline candidates; completes acquisitions or divestitures related to portfolio optimization; launches new oncology products or expands indications; reorganizations or corporate restructurings to focus on core oncology platform; expands geographic footprint or distribution capabilities; initiates significant operational expansions in R&D and GMP manufacturing capacity. Industry and segments: biopharmaceuticals; oncology; research and development; clinical-stage and mid-to-late-stage oncology assets; licensing and collaboration services; manufacturing and supply chain for oncology medicines. Target markets and customers: healthcare providers, hospitals, and oncology specialists; pharmaceutical distributors; research institutions and biopharma partners; patient populations across Europe and the Americas requiring cancer therapeutics. Subsidiaries/parent relationships: operates as PharmaMar S.A. with parent or group company relationships in the corporate structure; maintains affiliated R&D centers and manufacturing sites in Spain as part of its integrated oncology platform.
Company News
Pharma Mar, S.A. (PHMMF) Q2 2026 Earnings Call Transcript
Pharma Mar, S.A. (PHMMF) Shareholder/Analyst Call Transcript
PMV Pharmaceuticals Announces Board Chair Transition
Pharma Mar, S.A. (PHMMF) Q4 2025 Earnings Call Transcript
Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)
Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript